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Abstract— Surprisingly, lung disease is still one of the lead-
ing causes of deaths in the developed countries, including UK.  
According to the UK National Health Service (NHS), Chronic 
Obstructive Pulmonary Disease (COPD) is the fifth biggest 
killer disease in the UK, killing approximately 25,000 people a 
year. This problem is even worse in developing countries such 
as Vietnam, India and China, where air pollution is a big prob-
lem and the disease awareness is under-recognised. The NHS 
has set out one of its challenges is to identify people with lung 
disease earlier in the disease’s development pathway, in order 
to provide more effective and timely intervention and treat-
ment. This paper presents a novel Inspired Sinewave Device 
(ISD) to measure lung function and inhomogeneity. Both set of 
information are important for diagnosis and detection of early 
lung diseases. ISD has the potential to replace or supplement 
the traditional spirometry in the routine lung function testing. 
The paper describes both the principle of ISD and a set of 
experimental results demonstrating the capability of ISD to 
asymptotically detect asthmatic symptoms. Finally the paper 
discusses the future plan, including the testing of 300+ COPD 
patients at the Oxford Respiratory Trials Unit in UK, and the 
potential collaborations among research institutions in Vi-
etnam and UK about cost-effective and innovative develop-
ments of smart devices, biosensors, lab-on-chips and telehealth 
solutions for the routine lung function testing, diagnosis and 
evaluations of early lung diseases. 
Keywords— Lung Function Testing, Respiratory Disease, 
Asthma, Chronic Obstructive Pulmonary Disease, Medical 
Device 
I. INTRODUCTION  
 
According to the UK National Health Service (NHS), 
Chronic Obstructive Pulmonary Disease (COPD) is the fifth 
biggest killer disease in the UK, killing approximately 
25,000 people a year [1]. An estimated 3 million people 
have COPD in the UK. Although for around 2 million of 
this group, their COPD remains undiagnosed (Healthcare 
Commission 2006) [2]. 
In the early stages of COPD, patients are largely free of 
symptoms but, as the disease progresses, patients report 
symptoms of breathlessness, coughing and chest tightness. 
COPD primarily affects people aged over 45 and is charac-
terised by a chronic, slowly progressive decline in lung 
function, usually associated with exposure to cigarette 
smoke, but occasionally with exposure to air pollution or 
other noxious particles or gases. The total annual cost of 
COPD to the NHS is estimated to be over £800 million for 
direct healthcare costs, which equates to £1.3 million per 
100,000 people [2]. This problem is even worse in a devel-
oping country like Vietnam. With the population almost as 
twice as the UK, the problem is certainly bigger. Air pollu-
tion and smoking are the two biggest causes of COPD and 
are known problem in Vietnam. The numbers of smokers in 
developed countries have been steady or in a decline, 
whereas there is no sign of reducing in Vietnam. Moreover, 
due to limited resources of the healthcare system, the diag-
nosis, prevention, and treatment of the disease have not 
been addressed properly. Most people in Vietnam only go to 
hospitals when they are sick. At this time, COPD is already 
at a severe state and irreversible. There is a need for an 
accurate, affordable device acting as a screening test for 
lung function and disease, in order to identify people with 
disease early or encourage smoking cessation. 
The Inspired Sinewave Device (ISD) is a novel device to 
measure lung functions and inhomogeneity. Both sets of 
information are important to the diagnosis and evaluations 
of early lung diseases. It works by delivering small doses of 
tracer gases into the patient’s breaths and measuring the 
“response” in the expired breaths. By using an advanced 
model of the lung and circulatory system, the required pa-
rameters of the lung are estimated from the collected data. 
With this setup, the patients only require to breathe simulta-
neously through a mask. The technique does not rely on the 
patient’s effort, which is known to be unreliable in the tradi-
tional spirometry. In a way, the ISD aims to bridge the gap 
between the insensitive and unreliable traditional spirometry 
and the accurate but expensive imaging techniques (such as 
CT or MRI), as an affordable first-point-of-care screening 
test of lung function and disease. 
This paper describes the principle of the device, with 
more details having been given elsewhere [3-5]. This is 
followed by a presentation of two clinical studies demon-
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strating the capability of the device to measure functional 
residual capacity and lung inhomogeneity in a group of 
healthy and asymptotically asthmatic subjects. The paper 
then discusses the future plan of the project, including the 
testing of 300+ COPD patients at the Oxford Respiratory 
Trials Unit in UK. Finally, we discuss about the potential 
collaborations among research institutions in Vietnam and 
UK about the cost-effective and innovative development of 
devices for the routine lung function testing for diagnosis 




The method section describes the principle of the device 
and the setup of the 2 clinical studies.  
 
 
Fig.1 The hardware setup of the inspired sinewave device  
 
A. The principle of the Inspired Sinewave Device 
 
More details of the hardware and underlying mathemati-
cal equations have been described elsewhere [3-5]. We aim 
to give only a brief introduction here. 
 
Fig. 2 Raw Data from the ISD in a healthy volunteer. Green circles and red 
circles are the inspired concentration and the expired concentration of each 
breath. Green trace and red trace are the inspired sinewave and expired 
sinewave respectively. Red trace: [N2O] in expired gas. Arrows mark 
change in sine wave amplitude between inspired and expired gas 
The hardware setup of the current prototype of the device 
is given in Fig.1. The tracer gas, N2O in this case, is deliv-
ered to the patient through a nasal mask. The control system 
decides the amount of N2O based on the instantaneous flow 
of the breath. A N2O gas sensor and a flow sensor are 
mounted on the breathing circuit to measure the flow and 
concentration in real time. The control algorithm is imple-
mented in LabVIEW and the analysis and model are im-
plemented in Matlab. 
The mathematical principle of the device is as follows. 
By forcing the inspired concentrations of O2 and N2O to 
oscillate sinusoidally with very low amplitudes (3-5%) and 
low mean for N2O (3%), the expired concentrations of O2 
and N2O also follow a sinewave pattern (Fig. 2). Lung 
parameters then can be estimated from the responding 
amplitudes and phases of the expired concentrations. The 
larger the lung parameters, the greater are the attenuations 



















































EP : the magnitude of the expired sinewave 
IP : the magnitude of the inspired sinewave 
ON 2
 : the solubility of nitrous oxide in the blood 
PQ
 : the pulmonary blood flow (L/min) 
AV
 : the volume of gas ventilated by the lung (L/min) 
T : the sinewave period applied by the technique (mins) 
AV : the lung volume (L) 
Based on eq (1), AV and PQ
 can be estimated by 
measuring IE PP  /  at 2 or more periods. Interested 
readers can refer to more detailed publications [6], [7] for 
full mathematical description of the technique. 
 
B. The setup of the 2 clinical studies 
 
a) Clinical study I: Comparison with body 
plethysmography 
The aim of this study is to compare the functional residu-
al capacity (FRC) measured by the ISD and body plethys-
mography. Body plethysmography FRC was taken with a 
MasterScreen Body (Cardinal Health) body plethysmo-
graph, located in the Lung Function Laboratory, Churchill 
Hospital, Oxford UK. 32 healthy subjects with no history of 
cardiopulmonary diseases volunteered to participate in this 
study. Of which, 12 were female and 20 were male, 5 were 
active smokers.  Unless otherwise specified, participants 
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were taught to breathe in a relaxed way through airtight, 
surgical masks connected to the device. Participants were 
also reminded to keep their mouths sealed to prevent inci-
dences of gas leakage and were asked to relax in the ten 
minutes before measurement runs. Time period of the input 
tracer sinewave was fixed at 180 seconds (3 minutes) for the 
duration of this study. 
 The sinewave period of 3 minutes were chosen through 
extensive empirical test and simulation study. It was found 
that at 3-min sinwave, the estimated lung parameters were 
closest to the clinically meaningful values. The dependency 
of the estimated parameters on the period of the applied 
sinewave was actually an advantage and was used to inves-
tigate the lung inhomogeneity in the Clinical Study II be-
low. 
 
b) Clinical study II: Period response for investigation of 
lung inhomogeneity 
The aim of this study was to determine whether the time 
period response of a subjects’ lungs may also indicate the 
presence of ventilation inhomogeneity, which whilst more 
pronounced in some respiratory diseases e.g. asthma[8], 
may still exist to some degree in healthy subjects[9]. Seven-
teen healthy volunteers (11 male/6 female) were recruited. 
Six measurements of normal breathing into the ISD were 
made on each volunteer over a two hour period; the period 
of the applied sinewave was set at: 0.5 1, 2, 3, 4 and 5 mins, 
for each of the measurements respectively although the 
order in which they were performed was randomised.  
III. RESULTS 
A. Clinical study I: comparison study with body 
plethysmography 
The comparison was carried out in the form of a Bland 
Altman plot [10], and the result was shown in Fig. 3. The 
bias was estimated to be -0.68L, and the limits of agreement 
were 0.14L to -1.50L. The BIAS ± SD of -0.68 ± 0.42L 
showed that the ISD had similar precision to other tech-
niques when comparing with the body plethysmography 
(BP) in the literature [11, 12], demonstrating the capability 
of the ISD in measuring functional residual capacity. 
B. Clinical study II: Period response for investigating of 
lung inhomogeneity 
The result was displayed in the form of the ratio between 
the FRC measured by the ISD and the FRC measured by 
body plethysmography. Figure 4 shows the mean of the 
ratio over all subjects across the tested periods. It could be 
seen that the ratio in older asymptotic asthmatic subjects 
was both smaller and steeper as the period changed from 
4mins to 0.5mins. A smaller ratio suggested that “gas trap-
ping” existed in the lung. A steeper change of the ratio as 
the period changed suggested lung inhomogeneity. We 
therefore suggested the use of this ratio as an index to de-
scribe the level of lung inhomogeneity, with more details 













Fig.3 Bland Altman plot comparing FRC measured by the ISD and body 
plethysmography. Solid blue and red lines represent the bias and the limits 
of agreement respectively. Dashed lines show the 95% confidence intervals 
f these estimates. 
 
Fig. 4 The period response of the ratio between the FRC measured by the 
ISD and the body plethysmography, in 2 patient groups. We proposed to 
use this ratio as an index to investigate lung inhomogeneity. 
IV. DISCUSSION AND CONCLUSION 
On the back of the preliminary results, including the 
studies in this paper, we have secured a £0.7mil from the 
National Institute of Health Research Invention for Innova-
tion grant (UK), to further test the device for 2 applications: 
the continuous monitoring of lung function and blood flow 
of patients in operating theatres and intensive care units, and 
the lung function testing and diagnosis of outpatients with 
COPD. Our coming plan is to test the ISD on over 300 
patients with COPD over the next 2 years, at the Churchill 
hospital, Oxford, UK. The main aim of this study is to map 
the measurements obtained from the ISD with the assess-
ments from current standard COPD care, to validate wheth-
er the ISD is capable of detecting different levels of disease 
severity. The secondary aim of the study is to follow up 
Bland Altman Plot (n=44) 
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these patients over 3-5 years, to validate whether the ISD 
has a better predictive probability of disease deterioration 
over current standard tests. If this hypothesis is validated, 
the ISD will be a useful diagnostic tool to determine which 
patients should require further testing and earlier interven-
tion.  
The developed ISD is able to address the lung function 
testing and disease diagnosis, particularly the chronic ob-
structive pulmonary disease; it has potential impact in both 
developed and developing countries, including UK and 
Vietnam. Especially, Vietnam has a large population of 90 
millions. According to the World Economic Forum, Viet 
Nam is one of the ten countries with the worst air pollution 
among 132 countries whose environments were surveyed in 
relation to effects on human health. Also, according to the 
WHO, Viet Nam was among countries with the highest 
mortality rates due to ambient air pollution, 200-230 cases 
per million people per year. Moreover, in the low-income 
countries, the poor quality of diagnosis, detection of early 
diseases and cancer scanning leads to the survival rates of 
cancers and successful treatments of diseases are also much 
lower. By 2020, there will be between 15 and 17 million 
new cases of cancer every year, 60-70% new cases of can-
cer and nearly 70% of cancer deaths will be in economically 
disadvantaged countries [14].  
Followed the successful preliminary studies, the present 
and ongoing plan is to further validate the device in a larger 
group of COPD in the UK. This opens potential collabora-
tions among scientists in Vietnam and UK in both the tech-
nical development and the clinical trial of the device in 
hospital settings. Concretely, the following are the prelimi-
nary plan for RTD collaborations: (1) Technical collabora-
tion: to assist in developing, prototyping the hardware and 
instrumentation of components of the device, such as the 
sensing system; and (2) Clinical trial collaboration: to per-
form the trial of the device in hospital settings, exploring a 
new patient demographics, totally different from the UK 
patients in term of size, races, living conditions etc. Cost-
effective solutions for design and manufacture of the devic-
es should be the core objective.  In addition, with the recent 
advancements in micro &nano manufacturing, smart bio-
sensors and lab-on-chips can be developed for early detec-
tion of diseases and cancer screening. A research group at 
Hanoi University of Science and Technology has been 
working on developments of biosensors for characterization 
of cancer cells, early detections of diseases and cancer 
screening. These could be additional functions of ISD for 
effective diagnosis and evaluations of early lung diseases.    
A successful collaboration in Research & Technology 
Development (RTD) would strengthen the link between 
research institutions in Vietnam and UK, leading to the 
fruitful research results, and enhancements of human re-
sources developments in Biomedical Engineering for Vi-
etnam. Also, the successful developments of ISD  and col-
laborations between Vietnam and UK will have more 
potential impacts on a global scale, in both developed and 
developing countries,  especially RTD collaborations about 
the cost-effective and innovative developments of ISD, 
biosensors, lab-on-chips, and telehealth solutions for the 
routine lung function testing, diagnosis and evaluations of 
early lung diseases.  
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